Inventor · disambiguated record
David Dornan
Also filed as: DORNAN DAVID · DORNAN DAVID G
15 granted patents·24 pending applications·205 citations·filing 2002–2025
93Inventor score
Top patents by PatentIndex Score
39 records- 0197US8545850B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2010·Granted Oct 1, 2013·48 cites·8 claims
- 0296US8088378B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2008·Granted Jan 3, 2012·48 cites·5 claims
- 0395US9896506B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2015·Granted Feb 20, 2018·17 cites·27 claims
- 0494US8722857B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2009·Granted May 13, 2014·22 cites·53 claims
- 0594US8691531B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2011·Granted Apr 8, 2014·20 cites·9 claims
- 0691USRE48558EAnti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2018·Granted May 18, 2021·2 cites·70 claims
- 0789US2024309088A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 0888US10544218B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2016·Granted Jan 28, 2020·4 cites·61 claims
- 0986US10494432B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2013·Granted Dec 3, 2019·5 cites·118 claims
- 1086US7300905B2Methods for their manufacture of adsorbentQUESTAIR TECHNOLOGIES INC·Filed 2002·Granted Nov 27, 2007·38 cites·3 claims
- 1182US2022251197A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2022·Application pending·0 cites
- 1279US12325750B2Anti-Dectin-2 antibodies and methods of usingBOLT BIOTHERAPEUTICS INC·Filed 2023·Granted Jun 10, 2025·0 cites·29 claims
- 1376US2020247887A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2019·Application pending·0 cites
- 1473US11753474B2Anti-Dectin-2 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·0 cites·131 claims
- 1573US2025270329A1Anti-Dectin-2 AntibodiesBOLT BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1669US2020079852A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2019·Application pending·0 cites
- 1767US7785815B2COP1 molecules and uses thereofGENENTECH INC·Filed 2007·Granted Aug 31, 2010·1 cites·19 claims
- 1864US2014335107A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2014·Application pending·0 cites
- 1961US2022195066A1Anti-cea immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2053US2024033370A1Anti-pd-l1 immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2153US2018042905A1Methods of treating hepatitis b virusGILEAD SCIENCES INC·Filed 2017·Application pending·0 cites
- 2253US2024238430A1Anti-cea immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2351US9068230B2Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodiesDORNAN DAVID·Filed 2008·Granted Jun 30, 2015·0 cites·16 claims
- 2451US2023069055A1Anti-pd-l1 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2551US2023165968A1Cancer treatment methodsBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2649US2023293716A1Elastase-substrate, peptide linker immunoconjugates, and uses thereofBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2749US2016303095A1Methods of treating hepatitis b virusGILEAD SCIENCES INC·Filed 2016·Application pending·0 cites
- 2849US2023086603A1Anti-pd-l1 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2946US2022152215A1Immunoconjugates Targeting CEABOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3046US2022226492A1Immunoconjugates Targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3146US2022347312A1Immunoconjugate Synthesis MethodBOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3246US2022226491A1Immunoconjugates Targeting PD-L1BOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3346US2022143012A1Macromolecule-Supported TLR AgonistsBOLT BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3445US2008027004A1Phosphorylated COP1 molecules and uses thereofGENENTECH INC·Filed 2006·Application pending·0 cites
- 3538US10316049B2Tank-binding kinase inhibitor compoundsGILEAD SCIENCES INC·Filed 2016·Granted Jun 11, 2019·0 cites·59 claims
- 3638US2011045474A1Copi molecules and uses thereofDORNAN DAVID·Filed 2010·Application pending·0 cites
- 3736US9617600B2Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodiesDORNAN DAVID·Filed 2010·Granted Apr 11, 2017·0 cites·16 claims
- 3836US2014017230A1Chronic lymphocytic leukemia (cll) biomarkersHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 3932US2004132108A1Screening methods and agentsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Dornan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →